MT Newswires Live10-14
INmune Bio (INMB) and Quantum Computing (QUBT) said Wednesday that they will use quantum computing, artificial intelligence and data analytics to identify new potential applications for INmune's experimental Alzheimer's drug XPro.
The companies said they will analyze clinical and biological data to identify diseases that share the same underlying causes targeted by XPro, with an initial focus on rare diseases.
Financial details of the collaboration were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
